Revance Therapeutics (RVNC) Misses Q2 EPS by 17c, misses on revenue

Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.80), $0.17 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $58.13 million versus the consensus estimate of $58.88 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
• Pfizer reaffirms 2026 guidance after CFO transition news